利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.035 秒)

    PD-L2 Molecules: Novel PD-1 Ligands and Uses Therefor
    1.
    发明申请
    PD-L2 Molecules: Novel PD-1 Ligands and Uses Therefor 有权
    PD-L2分子：新型PD-1配体及其用途

    公开(公告)号：US20080118511A1

    公开(公告)日：2008-05-22

    申请号：US11765838

    申请日：2007-06-20

    申请人： Gordon Freeman ,  Irene Chernova ,  Tatyana Chernova ,  Nelly Malenkovich ,  Clive R. Wood

    发明人： Gordon Freeman ,  Irene Chernova ,  Tatyana Chernova ,  Nelly Malenkovich ,  Clive R. Wood

    IPC分类号： A61K39/395 ,  C12N5/00 ,  A61K38/16 ,  A61P35/00 ,  A61P37/06 ,  A61P31/00

    CPC分类号： G01N33/6854 ,  G01N33/5014 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/573 ,  G01N2800/52

    摘要： The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供分离的核酸分子，命名为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。 本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及已导入或破坏了PD-L2基因的非人类转基因动物。 本发明进一步提供分离的PD-L2多肽，融合蛋白，抗原肽和抗-PD-L2抗体。 本发明还提供了促进或抑制PD-L2与PD-1之间相互作用的方法。 还提供了利用本发明组合物的诊断和治疗方法。

    Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signal
    2.
    发明授权
    Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signal 有权
    识别在PD-1介导的信号存在下上调T细胞活化的化合物的方法

    公开(公告)号：US07432059B2

    公开(公告)日：2008-10-07

    申请号：US09895837

    申请日：2001-06-28

    申请人： Gordon Freeman ,  Irene Chernova ,  Tatyana Chernova ,  Nelly Malenkovich ,  Clive Wood ,  Yvette Latchman ,  Arlene H. Sharpe

    发明人： Gordon Freeman ,  Irene Chernova ,  Tatyana Chernova ,  Nelly Malenkovich ,  Clive Wood ,  Yvette Latchman ,  Arlene H. Sharpe

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6854 ,  G01N33/5014 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/573 ,  G01N2800/52

    摘要： The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. The invention further provides methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1-mediated signal. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供分离的核酸分子，命名为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。 本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及已导入或破坏了PD-L2基因的非人类转基因动物。 本发明进一步提供分离的PD-L2多肽，融合蛋白，抗原肽和抗-PD-L2抗体。 本发明还提供了促进或抑制PD-L2与PD-1之间相互作用的方法。 本发明还提供鉴定在PD-1介导的信号存在下上调T细胞活化的化合物的方法。 还提供了利用本发明组合物的诊断和治疗方法。

    Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
    8.
    发明申请
    Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor 审中-公开
    肿瘤细胞修饰以表达B7-2，增加免疫原性，并用于此

    公开(公告)号：US20050129670A1

    公开(公告)日：2005-06-16

    申请号：US10767561

    申请日：2004-01-28

    申请人： Gordon Freeman ,  Lee Nadler ,  Gary Gray

    发明人： Gordon Freeman ,  Lee Nadler ,  Gary Gray

    IPC分类号： A01K67/027 ,  A61K38/00 ,  C07K14/705 ,  C07K16/28 ,  C12N15/85 ,  A61K48/00

    CPC分类号： C12N15/8509 ,  A01K67/0271 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  A61K38/00 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2319/00 ,  C07K2319/30

    摘要： Tumor cells modified to express one or more T cell costimulatory molecules are disclosed. Preferred costimulatory molecules are B7-2 and B7-3. The tumor cells of the invention can be modified by transfection with nucleic acid encoding B7-2 and/or B7-3, by using an agent which induces or increases expression of B7-2 and/or B7-3 on the tumor cell or by coupling B7-2 and/or B7-3 to the tumor cell. Tumor cells modified to express B7-2 and/or B7-3 can be further modified to express B7. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed.

    摘要翻译： 公开了修饰以表达一种或多种T细胞共刺激分子的肿瘤细胞。 优选的共刺激分子是B7-2和B7-3。 本发明的肿瘤细胞可以通过用编码B7-2和/或B7-3的核酸转染，通过使用诱导或增加肿瘤细胞上B7-2和/或B7-3表达的试剂或通过 将B7-2和/或B7-3偶联到肿瘤细胞。 修饰以表达B7-2和/或B7-3的肿瘤细胞可进一步修饰以表达B7。 还公开了进一步修饰以表达MHC I类和/或II类分子或其中抑制MHC相关蛋白，不变链的表达的肿瘤细胞。 本发明的修饰的肿瘤细胞可用于治疗患有肿瘤的患者，预防或抑制肿瘤的转移性扩散或预防或抑制肿瘤复发的方法。 公开了特异性诱导针对肿瘤的CD4 + T细胞应答的方法和通过体内修饰肿瘤细胞治疗肿瘤的方法。

    Nucleic Acids Encoding proteins which induce immunological effector cell activation and chemattraction, vectors, and recombinant cells
    9.
    发明授权
    Nucleic Acids Encoding proteins which induce immunological effector cell activation and chemattraction, vectors, and recombinant cells 失效
    核酸编码诱导免疫效应细胞活化和化学吸收，载体和重组细胞的蛋白质

    公开(公告)号：US5238839A

    公开(公告)日：1993-08-24

    申请号：US732185

    申请日：1991-07-18

    申请人： Harvey I. Cantor ,  Roberto Patarca ,  Joel L. Schwartz ,  Gordon Freeman

    发明人： Harvey I. Cantor ,  Roberto Patarca ,  Joel L. Schwartz ,  Gordon Freeman

    IPC分类号： A61K38/00 ,  C07K14/52 ,  C07K16/24

    CPC分类号： C07K16/24 ,  C07K14/52 ,  A61K38/00 ,  C07K2317/77

    摘要： The present invention relates to genes and their encoded proteins which induce immunological effector cell activation and chemattraction. The proteins of the invention attract subsets of immunological effector cells and stimulate them to express their specialized effector cell functions. Such proteins, termed Ap-1 proteins, are expressed by lymphoid cells, and bind to effector cells such as macrophages and mast cells. In particular, the ApPursuant to the provisions of 35 U.S.C. .sctn.202(c), it is hereby acknoledged that the Governament has certain rights in this invention, which was made in part with funds from the National Institutes of Health.

    摘要翻译： 本发明涉及诱导免疫效应细胞活化和化学诱导的基因及其编码的蛋白质。 本发明的蛋白质吸引免疫效应细胞的子集并刺激它们表达其特异的效应细胞功能。 称为Ap-1蛋白的蛋白质由淋巴细胞表达，并结合效应细胞如巨噬细胞和肥大细胞。 特别地，Ap-1蛋白诱导巨噬细胞吞噬作用，II类主要组织相容性分子的表达，细胞毒性和迁移，并诱导造血祖细胞分化。 Ap-1分子在炎症或免疫疾病或肿瘤的治疗或诊断中可能是有价值的。